Incyte, Hengrui In ‘Biggest Ever’ China Pharma Out-Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
Incyte has acquired most global rights to an immuno-oncology antibody developed by China's Jiangsu Hengrui, in a deal worth up to nearly $800m plus royalties that will give the US firm a foothold in the PD-1 area and open up new combination therapies.
You may also be interested in...
Asia Deal Watch: Emmaus, Kainos Pursue R&D In Cancers With Limited Therapy Options
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Chordia Looks To Forge Own Path In Oncology
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
Quick Listen: Scrip’s Five Must-Know Things
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Need a specific report? 1000+ reports available
Buy Reports